The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| AORT | +66.76% | +169.78% | +21.96% | +1,119% |
| S&P | +17.53% | +93.66% | +14.13% | +1,429% |
Artivion, Inc. engages in the research and development of solutions which address cardiac and vascular surgeons' clinical challenges in treating patients with aortic diseases. Its products include aortic stents and stent grafts, prosthetic heart valves, cryopreserved cardiac and vascular allografts, and surgical sealants. It operates through the Medical Devices and Preservation Services segments. The Medical Devices segment includes aortic stents and stent grafts, surgical sealants, and On-X products. The Preservation Services segment offers cardiac and vascular tissue preservation services. The company was founded on January 19, 1984 and is headquartered in Kennesaw, GA.
There's nothing like an upside earnings surprise to juice the price of a company's shares.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $112.97M | 15.3% |
| Gross Profit | $69.69M | 17.4% |
| Gross Margin | 61.68% | 1.1% |
| Market Cap | $1.33B | 24.1% |
| Market Cap / Employee | $0.83M | 0.0% |
| Employees | 1.6K | 6.7% |
| Net Income | $1.34M | 163.4% |
| EBITDA | $16.52M | 16.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $53.48M | -2.8% |
| Accounts Receivable | $91.44M | 23.8% |
| Inventory | 86.7 | 7.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $258.00M | -28.0% |
| Short Term Debt | $5.74M | 37.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -2.20% | -1.1% |
| Return On Invested Capital | -2.95% | -0.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $11.72M | 223.7% |
| Operating Free Cash Flow | $15.01M | 144.7% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 3.77 | 3.93 | 3.73 | 4.51 | 24.36% |
| Price to Sales | 2.89 | 3.08 | 2.66 | 3.48 | 22.85% |
| Price to Tangible Book Value | -9.81 | -11.03 | -8.51 | -12.43 | 37.01% |
| Price to Free Cash Flow TTM | 119.62 | 101.30 | 108.38 | 184.16 | 89.64% |
| Enterprise Value to EBITDA | 102.37 | 148.34 | 131.15 | 98.14 | 0.87% |
| Free Cash Flow Yield | 0.8% | 1.0% | 0.9% | 0.5% | -47.27% |
| Return on Equity | -0.3% | -4.8% | -7.2% | -5.0% | 73.62% |
| Total Debt | $363.77M | $362.26M | $362.36M | $263.74M | -27.27% |
No podcast episodes available.
CRY earnings call for the period ending September 30, 2021.
CRY earnings call for the period ending June 30, 2021.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
